Patent-Related Notes from C&EN

April – 2017

Syngenta Patents Infringed:

Syngenta says a U.S. district court has found that the agrochemical maker Willowood infringed two Syngenta patents relating to the fungicide azoxystrobin. Damages for the infringement will be assessed at a trial later this year.

Solvay won a patent infringement lawsuit in China:

Solvay has won a patent infringement lawsuit in China against the Yantai-based firm Sunshow Specialty Chemical. The suit involved an ultraviolet stabilizer for thermoplastic olefins produced by Solvay’s Cytec Industries subsidiary.

10% of NIH Grants Directly Lead to Patents

According to Science (2017, DOI: 10.1126/science.aal0010), 10% of NIH Grants Directly Lead to Patents. Meanwhile, 30% of NIH grants are cited in patent applictions.   (See “By the numbers” – C&EN, 2017, 95 (14), pp 21–21April 3, 2017.)

The applied value of public investments in biomedical research

Abstract

Scientists and policy-makers have long argued that public investments in science have practical applications. Using data on patents linked to U.S. National Institutes of Health (NIH) grants over a 27-year period, we provide a large-scale accounting of linkages between public research investments and subsequent patenting. We find that about 10% of NIH grants generate a patent directly but 30% generate articles that are subsequently cited by patents. Although policy-makers often focus on direct patenting by academic scientists, the bulk of the effect of NIH research on patenting appears to be indirect. We also find no systematic relationship between the “basic” versus “applied” research focus of a grant and its propensity to be cited by a patent.

Steadymed wins IPR Challenge of United Therapeutics’s Remodulin® Product-by-Process Patent Claims

Final Decision – March 31, 2017

IPR2016-00006

STEADYMED LTD., (Petitioner)  v. UNITED THERAPEUTICS CORPORATION, (Patent Owner)

U.S. Patent No. 8,497,393 B2 “Process to Prepare Treprostinil, the Active Ingredient in Remodulin®”

Link to PDF: https://ptabdata.uspto.gov/ptab-api/documents/663936/native

Concert Pharma Sells Deuterated Version of Ivacaftor to Vertex

Vertex acquired rights to Concert Pharmaceuticals’s cystic fibrosis drug CTP-656. The drug is a deuterated version of Vertex’s own compound ivacaftor, which it sells under the name Kalydeco.

CTP-656 Currently in Phase II clinical trials. The deal avoided a potential litigation between the two companies.

CTP-656

CTP-656

Links:

BioSpace: “Vertex (VRTX) Inks Deal Worth $250 Million for Concert Pharma (CNCE)’s Cystic Fibrosis Drug”

C&EN: “Vertex Buys Concert’s Cystic Fibrosis Drug”

Juxtapid® Patents Survive IPR Challenge

March 6, 2017

Coalition for Affordable Drugs VIII LLC v. The Trustees of The University of Pennsylvania, IPR2015-01835 &  IPR2015-01836

 

 

A Lot of Excitement About the CRISPR Interference, or Rather Lack Thereof

In a nutshell, the Broad Institute’s patents (including US Patent No. 8,697,359) do not interfere with the University of California’s Patent Application (Serial Number 13/842,859).

Below are a quick selection of links for us to read more about it:

Patent Docs

http://www.patentdocs.org/2017/02/ptab-decides-crispr-interference-in-favor-of-broad-institute-their-reasoning.html
http://www.patentdocs.org/2017/02/ptab-decides-crispr-interference-no-interference-in-fact.html

IP Watchdog

https://www.ipwatchdog.com/2017/02/16/crispr-patent-interference-ended-uspto/id=78455/

The National Law Review

http://www.natlawreview.com/article/broad-institutemitharvard-crispr-patents-survive-pto-interference

Verified by MonsterInsights